PAM
SLS icon

Panagora Asset Management’s SELLAS Life Sciences SLS Stock Holding History

Panagora Asset Management’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-340
Closed -$21K – 2513
2018
Q3 		$21K Buy
+340
New +$23.5K ﹤0.01% 2213

Other funds holding SLS

6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Panagora Asset Management's SLS Position: Q4 2018 in Review

Panagora Asset Management sold out of SELLAS Life Sciences (SLS) in Q4 2018, closing a stake of 340 shares — an estimated $21K sold.

Panagora Asset Management first reported a position in SLS in Q3 2018 and held it in 1 quarter. The position peaked at $21K in Q3 2018. 20 funds tracked by Wall St. Rank hold SLS as of Q4 2018.

  • Panagora Asset Management reported no remaining SELLAS Life Sciences position as of Q4 2018 after selling out during the quarter.
  • Panagora Asset Management sold 340 SELLAS Life Sciences shares in Q4 2018, an estimated $21K.
  • Panagora Asset Management first reported a position in SELLAS Life Sciences in Q3 2018 and held it in 1 quarter.
  • Panagora Asset Management's SELLAS Life Sciences position peaked at $21K in Q3 2018.
  • 20 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q4 2018.

Based on Panagora Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.